Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Bladder cancer
Stage/Subtype:  stage IV bladder cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 69 for your search:
Start Over
Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D419BC00001, NCI-2015-02054, NCT02516241
A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: B9991001, NCI-2016-00304, 2015-003262-86, JAVELIN Bladder 100, NCT02603432
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: WO30070, NCI-2016-00967, 2016-000250-35, NCT02807636
Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-361, NCI-2016-01926, 163458, 2015-005731-41, NCT02853305
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-032, NCI-2013-02337, 2013-002844-10, NCT01928394
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA224-020, NCI-2014-00315, 2014-002605-38, NCT01968109
Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: INCB 54828-101, NCI-2015-00611, NCT02393248
A Phase 1b/2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: B-701-U21, NCI-2015-00701, NCT02401542
Ixazomib Citrate with Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients with Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0661, NCI-2015-00682, NCT02420847
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PLX108-14, NCI-2015-01614, KEYNOTE-103, NCT02452424
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: GEN702, NCI-2015-01770, NCT02552121
Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: E7080-A001-111, NCI-2016-00529, NCT02501096
Radiation Therapy in Preventing Brain Metastases in Patients with Locally Advanced or Metastatic Bladder or Urinary Tract Cancer Previously Treated with Chemotherapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2007-0933, NCI-2012-01675, NCT00756639
Gemcitabine Hydrochloride and Cisplatin in Treating Patients with High-Grade Urothelial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-208, NCI-2010-02376, NCT01261728
Gemcitabine Hydrochloride, Cisplatin, and Ipilimumab as First-Line Therapy in Treating Patients With Metastatic Urothelial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GU10-148, NCI-2013-00250, 1110007307, NCT01524991
An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PUMA-NER-5201, NCI-2014-00495, 2013-002872-42, NCT01953926
3D Conformal Radiation Therapy after Surgery in Treating Patients with High-Risk Bladder Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RAD2271-12, NCI-2013-01381, IRB00059097, NCT01954173
Gene Expression Profiling in Predicting Chemotherapy Response in Patients with Localized, Muscle-Invasive Bladder Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S1314, NCI-2014-00850, NCT02177695
Palbociclib in Treating Patients with Metastatic Urothelial Cancer after First-Line Chemotherapy Failure
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 1406, NCI-2015-00532, 14-2196, WI187190, NCT02334527
An Efficacy and Safety Study of JNJ-42756493 in Participants With Urothelial Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR105065, NCI-2015-00818, 2014-002408-26, 42756493BLC2001, NCT02365597
Regorafenib in Treating Patients with Advanced Urothelial Cancer After Chemotherapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 19 and over
Trial IDs: UAB1477, NCI-2015-01824, NCT02459119
Start Over